

The evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

COVID-19 vaccination in pregnancy, SARS-CoV-2 hybrid immunity, rebound infection following Paxlovid treatment

Peer reviewed journals featured:

- A randomised controlled trial of ensivibep for hospitalised COVID-19 adults [here](#)
- Narrative reviews on:
 - COVID-19 vaccination in pregnancy [here](#)
 - COVID-19-associated coagulopathy [here](#)
- Observational studies on:
 - Persistence of somatic symptoms after COVID-19 [here](#)
 - Prognostic significance of complement factors in severely ill COVID-19 patients [here](#)
 - Third COVID-19 vaccine dose effectiveness during the Omicron outbreak in Japan [here](#)
 - Preterm birth among pregnant persons with SARS-CoV-2 [here](#)
 - SARS-CoV-2 in-class transmission at a US university with public health mandates [here](#)
 - Occupational exposure to SARS-CoV-2 infection among healthcare personnel [here](#)
 - Effectiveness associated with Comirnaty (Pfizer) vaccine in ages 12 to 17 years [here](#)
 - COVID-19 vaccination response in patients with immune-mediated inflammatory disease [here](#) and associated commentary [here](#)
 - Seroprevalence and infection fatality rate of the Omicron variant in Denmark [here](#)
 - Machine learning forecast of pandemic effects on paediatric respiratory infections [here](#)
 - Medical students as health workers during COVID-19 [here](#)
- Commentary on:
 - SARS-CoV-2 hybrid immunity [here](#)
 - Addressing the long-term effects of COVID-19 [here](#)
 - Symptoms of long COVID attributable to SARS-CoV-2 infection [here](#)

Letters and correspondence discussed:

- Long COVID and gut dysbiosis linger beyond 1 year after SARS-CoV-2 clearance [here](#)
- SARS-CoV-2 and presymptomatic type 1 diabetes autoimmunity in children and adolescents [here](#)
- Two-year prevalence of altered sense of smell or taste in mildly symptomatic COVID-19 [here](#)
- Rate of SARS-CoV-2 reinfection during an Omicron wave in Iceland [here](#)
- Duration of symptoms and association with positive home rapid antigen test results after SARS-CoV-2 infection [here](#)

Pre-peer review articles featured:

- COVID-19 rebound after Paxlovid treatment [here](#)
- Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in long COVID [here](#)
- Distinguishing features of long COVID identified through immune profiling [here](#)
- Comparative pathogenicity of Omicron subvariants including BA.1, BA.2, and BA.5 [here](#)
- Neutralisation of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera [here](#)
- Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during Omicron wave [here](#)
- Long COVID impact quality of life at 6-, 12- and 18-months post-infection [here](#)
- Omicron BA.4/5 spike recognition and neutralisation elicited after the third mRNA vaccine dose [here](#)

Guidance and reports

- The World Health Organization published:
 - A rapid review on implications of the COVID-19 pandemic for patient safety [here](#)
 - Its weekly COVID-19 epidemiological report [here](#)

News and blogs

- Long-COVID treatments [here](#)
- What we know about the BA.4 and BA.5 Omicron variants [here](#)

[Click here](#) to subscribe to, or unsubscribe from, the evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on [COVID-19 transmission](#), SARS-CoV-2 [vaccines](#), and [variants](#) of concern, and [post-acute sequelae of COVID-19 \(long COVID\)](#).